Argent Biopharma Ltd

RGT

Company Profile

  • Business description

    Argent Biopharma Ltd is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. Its assets, CannEpil and CimetrA, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others. Its geographic areas are Malta, Slovenia and others, and Australia. The group generates the majority of its revenue from Slovenia and others.

  • Contact

    295 Rokeby Road
    Suite 1
    SubiacoWA6008
    AUS

    T: +61 865552950

    E: [email protected]

    https://www.argentbiopharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    30 June 2026

    Employees

Stocks News & Analysis

stocks

ASX listed bank overvalued despite strong earnings

Profit beats drive shares higher for Australia’s largest asset manager.
stocks

After earnings, is Amazon a buy, a sell, or fairly valued?

After the launch of Amazon Supply Chain Services, here’s what we think of the stock.
stocks

ASX retail share expected to recover despite choppy conditions

Weakening consumer demand a temporary headwind for ASX retailer.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,942.4014.500.16%
CAC 408,056.3856.19-0.69%
DAX 4024,350.2811.650.05%
Dow JONES (US)49,704.4795.310.19%
FTSE 10010,269.4336.360.36%
HKSE26,406.8413.130.05%
NASDAQ26,274.1327.050.10%
Nikkei 22562,417.88295.77-0.47%
NZX 50 Index13,210.4835.350.27%
S&P 5007,412.8413.910.19%
S&P/ASX 2008,701.8011.500.13%
SSE Composite Index4,225.0245.071.08%

Market Movers